Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a pilot feasibility study of 40 pregnant women to test the investigators' recruitment, enrollment and randomization procedures in preparation to conduct a larger randomized control trial to compare diagnostic methods for gestational diabetes. The two methods that are being compared are the 2 hour 75 gram OGGT (2011 ADA guidelines) versus a 1 hour 50 gram GCT + 3 hour 100 gram OGTT if the 1 hour result is abnormal (Carpenter and Coustan criteria).
This is a pilot feasibility study of 40 pregnant women between 24-28 weeks gestation to test the investigators recruitment, enrollment and randomization procedures in preparation to conduct a larger randomized control trial to compare diagnostic methods for gestational diabetes.
Forty women 18 years of age or older will be recruited at 20-24 weeks pregnancy from the ob/gyn outpatient practices at Magee-Women's hospital (MWH). Eligible women will return to MWH main lab between 24-28 weeks gestation for the routine 1 hour 50gm glucose challenge test. Women with blood glucose values less than 200 will be randomized to receive either the fasting 2 hour 75 gm oral glucose tolerance test (OGTT)or the 3 hour 100 gm OGGT within two weeks. Gestational diabetes will be determined for the 2 hour 75 gm OGGT arm based on the 2011 ADA guidelines and the 3 hour 100 gm OGGT arm based on the Carpenter and Coustan criteria. Patients and their providers will be informed of the diagnosis of gestational diabetes, but they will be blinded to the criteria used to make the diagnosis as well as the specific results of glucose tolerance testing.
Chart reviews will be conducted to assess for perinatal maternal and infant health factors (e.g.pregnancy weight, gestational weight gain, co morbidities) as well as for data on perinatal outcomes related to GDM such as macrosomia, c-sections, and birth trauma. Two brief self-administered questionnaire will assess participants' views on screening for gestational diabetes and assess participants experience with and solicit feedback on the study procedures.
At the end of this pilot study, the investigators will have experience with recruitment, retention, and randomization procedures and have made the necessary protocol revisions. If successful, this feasibility study will provide the preliminary data and feasibility justification needed to conduct a larger randomized control trial to compare the effectiveness of two diagnostic methods for gestational diabetes.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 75 Gram OGTT | Active Comparator | The 2011 ADA criteria will be used to diagnose gestational diabetes in this study arm. |
|
| 100 gram OGTT | Active Comparator | A 2 step approach to the diagnosis of gestational diabetes will be used in this arm. Patients who have a 50 gram, 1 hour glucose challenge test result greater than 135 mg/dL will be diagnosed with gestational diabetes if their 3 hour, 100 gram OGTT results exceed the diagnostic threshold recommended by Carpenter and Coustan. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dietary modification and medications | Behavioral | Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control. |
| Measure | Description | Time Frame |
|---|---|---|
| Macrosomia | Defined as birthweight >90th percentile for gestational age or birthweight >4000 grams | Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation) |
| Cesarean delivery | Primary or repeat cesarean delivery | Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation) |
| Diagnosis of gestational diabetes | Assess how frequently a diagnosis of gestational diabetes is made | Will be followed from study enrollment until delivery (approximately 40 weeks' gestation) |
| Measure | Description | Time Frame |
|---|---|---|
| Pre-eclampsia or gestational hypertension | New onset hypertension +/- proteinuria | Will be assessed from study enrollment until 30 days after delivery |
| Neonatal hypoglycemia | Defined as blood glucose less than 80 mg/dL from heel stick within 1 hour after delivery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christina M Scifres, MD | University of Pittsburgh | Principal Investigator |
| Esa Davis, MD MPH | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Magee-Womens Hospital | Pittsburgh | Pennsylvania | 15213 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016640 | Diabetes, Gestational |
| ID | Term |
|---|---|
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D003920 | Diabetes Mellitus |
Not provided
Not provided
| ID | Term |
|---|---|
| D004035 | Diet Therapy |
| D004304 | Dosage Forms |
| ID | Term |
|---|---|
| D044623 | Nutrition Therapy |
| D013812 | Therapeutics |
| D004364 | Pharmaceutical Preparations |
| D013678 | Technology, Pharmaceutical |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| First 24 hours of life |
| Neonatal hyperbilirubinemia | Defined as bilirubin greater than 5 mg/dL over 24 hours from heel stick | First 7 days of life |
| Infant birth trauma | Defined as shoulder dystocia/brachial plexus injuries | Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation) |
| Maternal birth trauma | 3rd or 4th degree perineal laceration or postpartum hemorrhage | Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation) |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D008919 |
| Investigative Techniques |